Pleven

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease4 trials
• Familial hypercholesterolaemia3 trials
• Stroke3 trials
• Multiple sclerosis2 trials
• Acute myeloid leukaemia1 trial
• Atopic dermatitis (eczema)1 trial
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Chronic spontaneous urticaria1 trial
• High blood pressure1 trial
• Myeloproliferative neoplasms1 trial
• Peripheral artery disease1 trial
• and 1 more

Phase

• Phase 37 trials
• Phase 22 trials
• Phase 42 trials

Status

• Active, not recruiting6 trials
• Completed4 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals11 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT07220577· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis1 recruiting

Closed trials

• Completed

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

  NCT05030311· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source